440 Participants Needed

Zanzalintinib for Neuroendocrine Tumors

(STELLAR-311 Trial)

Recruiting at 1 trial location
EC
Overseen ByExelixis Clinical Trials
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Research Team

MD

Medical Director

Principal Investigator

Exelixis

Eligibility Criteria

This trial is for people with advanced or widespread neuroendocrine tumors, including pancreatic ones. Participants must have measurable disease, confirmed by tests and scans, and should have seen their cancer grow despite past treatments. They need to provide tumor tissue samples if possible.

Inclusion Criteria

My cancer can be measured by standard health scans.
My cancer is a well-differentiated, advanced or metastatic NET from the pancreas or another organ.
I have had treatments for my neuroendocrine tumor based on its location and how it functions.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either zanzalintinib or everolimus oral tablets once daily

14 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Everolimus
  • Zanzalintinib
Trial Overview The study compares the effectiveness of two drugs: Zanzalintinib and Everolimus. Patients who've had previous treatments for neuroendocrine tumors will be randomly assigned to receive either drug to see which one works better.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: ZanzalintinibExperimental Treatment1 Intervention
Participants will receive zanzalintinib oral tablets once daily for up to 14 months.
Group II: EverolimusActive Control1 Intervention
Participants will receive everolimus oral tablets once daily for up to 14 months.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Exelixis

Lead Sponsor

Trials
126
Recruited
20,500+
Michael M. Morrissey profile image

Michael M. Morrissey

Exelixis

Chief Executive Officer since 2010

PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin

Vicki L. Goodman profile image

Vicki L. Goodman

Exelixis

Chief Medical Officer since 2022

MD

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security